Neurodegenerative diseases such as Huntington’s remain incurable, leaving patients and families without treatment or hope.

Dr. Laure Jamot and Professor Frédéric Saudou founded HuntX Pharma in December 2022 to  address the root cause: defects in axonal transport, a key mechanism for neuronal communication.

The biotech is developing HX127, a molecule capable of restoring axonal transport—without relying on gene therapy.

👉 Already supported by a €1.7M seed round and winner of the I-Nov competition (France 2030) with an additional €2M, the startup is now preparing its first clinical trials.

🫰 An innovation that could extend beyond Huntington’s disease and open the way to treatments for other neurodegenerative pathologies.

Discover HuntX Pharma